Associated tags: Environment, Benefit corporation, GHG, Pharmaceutical industry, Patient, Chiesi Farmaceutici, Health, Research
Locations: MA, HIVES, RARE, JAPAN, LAWRENCE, PL, ADA, AM, CALIFORNIA, ITALY, MASSACHUSETTS, FRANCE, US, CHINA, EUROPE, UK
ENDO,
Abstract,
MACRO,
Barrow Neurological Institute,
University,
Capsule,
Safety,
FRCP,
Neurosurgery,
Endocrine system,
University of Arizona,
FACE,
Post hoc analysis,
Lipodystrophy,
Pharmaceutical industry BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.
Key Points:
- BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.
- Attendees can visit Chiesi Global Rare Diseases product booth #526 and the medical booth #428.
- Poster presentations include the latest data from the Chiesi Management of Acromegaly (MACRO) registry and a presentation on the Lipodystrophy Severity Scoring tool to assess the disease burden in lipodystrophy.
- To register for ENDO 2024 and view the full meeting schedule, visit the Endocrine Society’s website here .
Atmosphere of Earth,
Area studies,
Kidney,
Respiratory disease,
American Thoracic Society,
Treatment,
Sapphire,
Conference,
Annual,
Research,
Pharmacokinetics,
Innovation Hub,
Clinical trial,
RV,
ATS,
Chronic obstructive pulmonary disease,
Abstract,
Safety,
Obstructive lung disease,
Gold,
Behavioural sciences,
Health services research,
CARY,
Pharmaceutical industry "Alongside updates on our scientific progress, the Chiesi expert-led Innovation Hub will focus on discussing the role of small airway dysfunction and persistent airflow limitation in asthma.
Key Points:
- "Alongside updates on our scientific progress, the Chiesi expert-led Innovation Hub will focus on discussing the role of small airway dysfunction and persistent airflow limitation in asthma.
- These presentations underscore Chiesi's dedication to advancing scientific knowledge and improving outcomes for people living with respiratory disease with preclinical and clinical stage global studies.
- “The creation of innovative medicines offers increased treatment options and opportunities for treatment better tailored to an individual’s specific needs.
- Chiesi is also sponsoring a one-year research grant for a respiratory disease researcher to advance the understanding of obstructive lung disease.
Research,
Baby,
Maternity,
Clinical Trials,
Biotechnology,
Health,
Consumer,
Pharmaceutical,
General Health,
Science,
Patient,
Disease,
Bronchopulmonary dysplasia,
OHB,
Clinical trial,
Trial of the century,
Safety,
Premature,
BPD,
Place of birth,
Neonatology "As a neonatologist, I’m thrilled that we have restarted this groundbreaking clinical trial previously paused during the out-licensing process to Oak Hill Bio.
Key Points:
- "As a neonatologist, I’m thrilled that we have restarted this groundbreaking clinical trial previously paused during the out-licensing process to Oak Hill Bio.
- OHB-607 can potentially improve the outcomes for infants born extremely premature," said Victoria Niklas, Chief Medical Officer at Oak Hill Bio.
- “At Oak Hill Bio, we are committed to advancing the field of neonatology and delivering the best possible care and outcomes to patients together with our partners at Chiesi."
- “The restart of this study marks a significant milestone highlighting the shared commitment of Chiesi and Oak Hill Bio to advance solutions for the vulnerable group of extremely premature infants,” commented Diego Ardigò, Global Research & Development Head at Chiesi Group.
Partnership,
Patient,
Drug,
Organization,
Health,
Respiratory disease,
Drug development,
Premature,
Research,
Competence,
Neonatology,
Pharmaceutical industry PARMA, Italy, May 14, 2024 /PRNewswire/ -- Chiesi Group, a research-oriented international biopharmaceutical group, proudly announces the signing of a memorandum of understanding with Karolinska Institutet, a medical university.
Key Points:
- PARMA, Italy, May 14, 2024 /PRNewswire/ -- Chiesi Group, a research-oriented international biopharmaceutical group, proudly announces the signing of a memorandum of understanding with Karolinska Institutet, a medical university.
- The agreement solidifies a commitment between the two organizations to collaborate on joint efforts aimed at advancing therapeutic solutions for urgent health challenges.
- The landmark collaboration between Chiesi and Karolinska Institutet (KI), will accelerate research and development initiatives for respiratory diseases, rare diseases, diseases of prematurity, and other specialty care indications.
- Chiesi Group and KI will exchange ideas, expertise, and resources to accelerate the translation of scientific discoveries into tangible healthcare solutions.
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Cardiology,
Biotechnology,
Patient,
EDT,
Pulmonary hypertension,
GOSS,
PAH,
Partnership,
ILD,
Entrepreneurship,
Disease,
Prevalence,
Orthostatic hypertension,
Pharmaceutical industry Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.
Key Points:
- Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.
- While many approved PAH treatments are available, most are primarily vasodilators and do not impact the progressive course of the disease.
- Gossamer and Chiesi plan to initiate a global Phase 3 registrational study in PH-ILD in mid-2025 and to evaluate seralutinib in additional indications of high unmet need.
- Chiesi will have the exclusive right to commercialize seralutinib outside of the US and will pay Gossamer an escalating mid-to-high teens royalty on net sales.
AIR,
U.S. AIR,
Chronic obstructive pulmonary disease,
Health,
Leo Pharma,
History,
Smith,
Patient,
Asthma,
Organization,
COPD Chiesi USA remains steadfast in its preparations for the full-scale U.S. launch of its AIR franchise as part of the company’s commitment to improving respiratory care and health in communities
Key Points:
- Chiesi USA remains steadfast in its preparations for the full-scale U.S. launch of its AIR franchise as part of the company’s commitment to improving respiratory care and health in communities
CARY, N.C., April 15, 2024 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.
- Smith will report to Jon Zwinski, CEO and general manager of Chiesi USA.
- “Richard’s inspirational leadership and track record of enabling actionable programs with multistakeholder engagement reflect Chiesi USA’s mission and values.
- Before joining Chiesi USA, Smith was vice president and head of the U.S. commercial organization at LEO Pharma, Inc.
Retrieved on:
Wednesday, April 24, 2024
Pain,
Enzyme replacement therapy,
Hearing loss,
Fabry disease,
ERT,
Genetics,
Disease,
LGC,
Patient,
Fatigue,
Perception,
Quality of life,
Pharmaceutical industry BOSTON, April 24, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases.
Key Points:
- - Real-world evidence provides valuable insights about the management and monitoring of patients with Fabry disease for healthcare providers, researchers, and industry partners -
BOSTON, April 24, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases.
- "There continues to be a general lack of awareness and a limited appreciation of the numerous unique challenges that rare disease patients face every day, including those who are living with Fabry disease," said Giacomo Chiesi, head of Chiesi Global Rare Diseases.
- The results of this survey will help us partner with healthcare providers to improve the care of patients with Fabry disease by addressing their most relevant unmet needs."
- "Our analysis highlights the gap between current standard-of-care in disease monitoring and patient perception of disease progression among patients with Fabry disease."
Carbon,
Science,
Corporation,
Enzyme replacement therapy,
FDA,
AIR,
License,
International,
RARE,
Investment,
Climate,
Fabry disease,
Climate change,
CER,
B Corporation (certification),
CDP,
Partnership,
Empowerment,
Alpha-mannosidosis,
Parent,
CARE,
Chronic obstructive pulmonary disease,
Environment,
Culture,
Benefit corporation,
Patient,
Science Based Targets initiative,
Bronchiectasis,
Acquisition,
Caregiver,
Epidermolysis bullosa,
GHG,
Place of birth,
Health,
Neonatology,
Ethics,
Asthma,
RDS,
Infant respiratory distress syndrome,
Growth,
Carbon Disclosure Project,
COPD,
Pharmaceutical industry PARMA, Italy, April 22, 2024 /PRNewswire/ -- In 2023, Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma (Italy), with 31 affiliates worldwide, showcased the efficacy of its operating model centred around shared value, sustainability, and high ethical standards. Through this approach, Chiesi continues to deliver tangible benefits for patients, people, and the planet.
Key Points:
- Chiesi's fixed triple formulation for the treatment of asthma and COPD (Chronic Obstructive Pulmonary Disease) achieved a 27% @CER growth.
- Also, in 2023 it was introduced in China, presenting a pivotal opportunity for growth and expanding access to treatment for more patients.
- In March 2023, Chiesi enriched its AIR portfolio thanks to the partnership with Affibody AB to develop and commercialize innovative treatments for respiratory diseases.
- In November 2023, Chiesi signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel solution for bronchiectasis.
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced the launch of Rethink Acromegaly, a disease education program. Intended to provide audiences with the latest information and resources, RethinkAcromegaly.com serves as a resource to empower people living with acromegaly, their caregivers, and healthcare professionals.
Key Points:
- Intended to provide audiences with the latest information and resources, RethinkAcromegaly.com serves as a resource to empower people living with acromegaly, their caregivers, and healthcare professionals.
- Acromegaly is a rare endocrine disorder characterized by excessive growth hormone production, typically stemming from a benign pituitary tumor.
- "At Chiesi Global Rare Diseases, we understand that developing medicines for underserved patient communities is just one piece of the puzzle.” Giacomo Chiesi, Head of Chiesi Global Rare Diseases, said.
- “Equipping individuals with rare diseases, caregivers, and their healthcare providers with the knowledge and resources they need to navigate their disease is equally vital.
Retrieved on:
Thursday, February 8, 2024
Conjunctivitis,
Arthralgia,
Anaphylaxis,
Common,
ADAS,
Birth,
Prevalence,
Velmanase alfa,
Fabry disease,
Human,
Diagnosis,
Headache,
Cough,
Erythema,
ERT,
Glycogen storage disease,
Alpha-mannosidosis,
DSM-IV codes,
Vomiting,
Hospital,
Incidence,
Patient,
Rash,
Nursing,
Data,
Chills,
Enzyme replacement therapy,
Pharmaceutical industry BOSTON, Feb. 8, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the presentation of long-term data from up to 12 years of treatment with velmanase alfa in patients with alpha-mannosidosis (AM). The company also announced the presentation of immunogenicity and tolerability data from its pegunigalsidase alfa clinical trial program in Fabry disease, as well as analyses of the prevalence, diagnosis, and progression of these rare lysosomal storage disorders. The data are being presented during the 20th Annual WORLDSymposium™ Research Meeting that is being held February 4-9, 2024, in San Diego, California.
Key Points:
- The data are being presented during the 20th Annual WORLDSymposium™ Research Meeting that is being held February 4-9, 2024, in San Diego, California.
- Several poster presentations are highlighting immunogenicity and tolerability data from the pegunigalsidase alfa clinical trial program in Fabry disease.
- The analysis includes 108 patients, 27 (25%) of whom were ADA+ before receiving their first dose of pegunigalsidase alfa.
- There was a low incidence of de novo ADAs (n=17) occurring predominantly in the first year of treatment with pegunigalsidase alfa.
